Ross D J, Jordan S C, Nathan S D, Kass R M, Koerner S K
Division of Pulmonary Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Chest. 1996 Apr;109(4):870-3. doi: 10.1378/chest.109.4.870.
There is no consensus regarding the optimal induction immunosuppression regimen after lung transplantation (LT). In addition to the potential benefit of a reduced incidence of early acute allograft rejection, cytolytic induction immunosuppression may impact on long-term allograft function. We retrospectively assessed our incidence of obliterative bronchiolitis syndrome (OBS) stages Ia and IIa in LT survivors given two different cytolytic induction immunosuppression regimens: (between March 1989 and October 1990) OKT3 (5 mg/d)x10 to 14 days (n=11) vs (between November 1990 and April 1993) Minnesota antilymphocyte globulin (MALG) (10 to 15 mg/kgdx5 to 7 days. Cyclosporine (CSA) (whole blood polyclonal assay=600 to 800 ng/mL), azathioprine (1 to 2 mg/kg/d), and maintenance prednisone (0.2 mg/kg/d) were similar. Surveillance spirometry was performed monthly, in accordance with accepted American Thoracic Society criteria. Fiberoptic bronchoscopy with transbronchial biopsies (TBBs) were performed for clinical indications. Surveillance TBBs were not performed during the era of this study. As defined by the ISHLT "Working Formulation for the Standardization of Nomenclature and for Clinical Staging of Chronic Dysfunction in Lung Allografts," latencies to development of OBS stages Ia and IIa were determined by Kaplan-Meir analysis. Stepwise regression (Cox proportional hazards model) was performed for the variables: cytolytic induction regimen, episodes cytomegalovirus (CMV) pneumonitis, episodes CMV infection, serologic CMV donor (+): recipient (-) mismatch, prior pregnancy, HLA (A,B,DR +/- DQ) mismatches, episodes greater than grade A1 acute cellular rejection (ACR). We found that the OKT3 cohort experienced longer latencies for OBS stages Ia and IIa. Latencies to OBS stages Ia for OKT3 ve MALG were 962 +/- 65 vs 354 +/- 85 days (X +/- SEM) respectively. Brookmeyer-Crowley 95% confidence intervals for median latencies were 744 to 1,180 vs 266 to 510 days for OKT3 vs MALG, respectively. The Cox model was significant only for the variable of the induction cytolytic immunosuppression regimen (p=0.0015). By physiologic criteria, a longer course of OKT3 appeared superior to the short-course MALG protocol in delaying chronic lung allograft dysfunction. These effects may be related either to inherent differences in the antilymphocyte preparations or, alternatively, the difference in duration of treatment between groups. Surveillance TBB and treatment of detected occult ACR may serve to negate the observed differences in latencies for OBS.
关于肺移植(LT)后最佳诱导免疫抑制方案尚无共识。除了可能降低早期急性移植物排斥发生率的潜在益处外,溶细胞性诱导免疫抑制可能会影响长期移植物功能。我们回顾性评估了接受两种不同溶细胞性诱导免疫抑制方案的LT幸存者中闭塞性细支气管炎综合征(OBS)Ia期和IIa期的发生率:(1989年3月至1990年10月)OKT3(5mg/d)×10至14天(n = 11)与(1990年11月至1993年4月)明尼苏达抗淋巴细胞球蛋白(MALG)(10至15mg/kg/d×5至7天)。环孢素(CSA)(全血多克隆测定=600至800ng/mL)、硫唑嘌呤(1至2mg/kg/d)和维持用泼尼松(0.2mg/kg/d)相似。根据美国胸科学会公认的标准,每月进行一次监测肺功能测定。根据临床指征进行经支气管活检(TBB)的纤维支气管镜检查。在本研究期间未进行监测性TBB。根据国际心脏和肺移植学会(ISHLT)“肺移植慢性功能障碍命名标准化和临床分期工作方案”的定义,通过Kaplan-Meir分析确定OBS Ia期和IIa期发展的潜伏期。对以下变量进行逐步回归(Cox比例风险模型):溶细胞性诱导方案、巨细胞病毒(CMV)肺炎发作次数、CMV感染发作次数、血清学CMV供体(+):受体(-)错配、既往妊娠、HLA(A、B、DR +/- DQ)错配、大于A1级急性细胞排斥(ACR)发作次数。我们发现OKT3组的OBS Ia期和IIa期潜伏期更长。OKT3组和MALG组的OBS Ia期潜伏期分别为962±65天和354±85天(X±SEM)。OKT3组和MALG组中位潜伏期的Brookmeyer-Crowley 95%置信区间分别为744至1180天和266至510天。Cox模型仅对诱导溶细胞性免疫抑制方案变量具有显著性(p = 0.0015)。根据生理学标准,较长疗程的OKT3在延迟慢性肺移植功能障碍方面似乎优于短疗程的MALG方案。这些影响可能与抗淋巴细胞制剂的内在差异有关,或者与两组治疗持续时间的差异有关。监测性TBB和对检测到的隐匿性ACR的治疗可能会消除观察到的OBS潜伏期差异。